(Q48249715)

English

Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors

scientific article published on 22 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

author name string

F Gressier

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

C Verstuyft

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

P Hardy

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

L Becquemont

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

E Corruble

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

publication date

22 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

Journal of Neural Transmission

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

122

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

35-42

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

5-HTTLPR modulates antidepressant efficacy in depressed women.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

CYP2C19 variation and citalopram response

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Pharmacogenetics of antidepressant medication intolerance

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Applications of CYP450 testing in the clinical setting

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Personalized medicine: is it a pharmacogenetic mirage?

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

1 reference

https://api.crossref.org/works/10.1007%2FS00702-014-1273-4

21 January 2018

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid detection of common cytochrome P450 2D6 alleles in Caucasians

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25047911

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00702-014-1273-4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/25047911

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48249715&oldid=2209257186"